AI Article Synopsis
- * The text reports a case of a 50-year-old woman with mCRC who achieved a complete metabolic response after treatment with FOLFIRI-aflibercept, assessed via FDG PET/CT.
- * This case highlights the potential of FDG PET/CT as an effective tool for evaluating the effectiveness of targeted therapies in mCRC.
Article Abstract
FOLFIRI-aflibercept chemotherapy is indicated in second-line treatment of metastatic colorectal cancer (mCRC) after progression under FOLFOX (±bevacizumab). Nevertheless, its proven therapeutic efficacy in clinical trials was based on partial responses. And to date, only 2 cases of complete response assessed by CT were reported in literature. We report a complete metabolic response assessed by FDG PET/CT in a 50-year-old woman with mCRC treated by FOLFIRI-aflibercept. This also confirms that FDG PET/CT is emerging as a useful approach for therapeutic assessment of targeted drugs in mCRC.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/RLU.0000000000002611 | DOI Listing |
Publication Analysis
Top Keywords
response assessed
12
fdg pet/ct
12
complete metabolic
8
metabolic response
8
assessed fdg
8
second-line treatment
8
treatment metastatic
8
metastatic colorectal
8
colorectal cancer
8
pet/ct folfiri-aflibercept
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!